HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Keith A Ching Selected Research

N- (2- (6- (4- cyclobutylamino- 5- trifluoromethylpyrimidine- 2- ylamino)- 1,2,3,4- tetrahydro- 1,4- epiazano- naphthalen- 9- yl)- 2- oxo- ethyl)acetamide

3/2012An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Keith A Ching Research Topics

Disease

8Neoplasms (Cancer)
12/2021 - 01/2012
2Stomach Neoplasms (Stomach Cancer)
02/2012 - 01/2012
1Carcinoma (Carcinomatosis)
12/2021
1Experimental Melanoma
10/2021
1Residual Neoplasm
12/2020
1Breast Neoplasms (Breast Cancer)
12/2020
1Renal Cell Carcinoma (Grawitz Tumor)
11/2020
1Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
01/2020
1Fatigue
01/2020
1Lymphoma (Lymphomas)
01/2020
1Small Cell Lung Carcinoma (Small Cell Lung Cancer)
03/2012
1Colonic Neoplasms (Colon Cancer)
03/2012
1Retinoblastoma (Glioblastoma, Retinal)
03/2012
1Neurodegenerative Diseases (Neurodegenerative Disease)
07/2003
1Machado-Joseph Disease (Spinocerebellar Ataxia Type 3)
07/2003

Drug/Important Bio-Agent (IBA)

4Biomarkers (Surrogate Marker)IBA
12/2021 - 03/2012
2avelumabIBA
12/2021 - 11/2020
2Pharmaceutical PreparationsIBA
03/2012 - 01/2012
2Tyrosine Kinase InhibitorsIBA
02/2012 - 01/2012
1Immune Checkpoint InhibitorsIBA
12/2021
1Biological ProductsIBA
12/2021
1Interleukin-15 (Interleukin 15)IBA
10/2021
1Sunitinib (Sutent)FDA Link
11/2020
1Axitinib (AG 013736)IBA
11/2020
1LigandsIBA
11/2020
1Rituximab (Mabthera)FDA Link
01/2020
1utomilumabIBA
01/2020
1Insulin-Like PeptidesIBA
12/2013
1Insulin-Like Growth Factor Binding Protein 5IBA
12/2013
1figitumumabIBA
12/2013
1Insulin Receptor Substrate ProteinsIBA
12/2013
1N- (2- (6- (4- cyclobutylamino- 5- trifluoromethylpyrimidine- 2- ylamino)- 1,2,3,4- tetrahydro- 1,4- epiazano- naphthalen- 9- yl)- 2- oxo- ethyl)acetamideIBA
03/2012
1Aurora Kinase BIBA
03/2012
1Aurora Kinase AIBA
03/2012
1Lapatinib (GW572016)FDA Link
02/2012
1ErbB Receptors (EGF Receptor)IBA
02/2012
1Gefitinib (Iressa)FDA Link
02/2012
1Trastuzumab (Herceptin)FDA Link
02/2012
1dacomitinibIBA
02/2012
1Canertinib (CI 1033)IBA
02/2012
1Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA
02/2012
1AfatinibIBA
02/2012
1Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
01/2012
12- (4- (3- quinolin- 6- ylmethyl- 3H- (1,2,3)triazolo(4,5- b)pyrazin- 5- yl)pyrazol- 1- yl)ethanolIBA
01/2012
1Proto-Oncogene Proteins c-metIBA
01/2012
1polyglutamineIBA
07/2003
1Ataxin-3IBA
07/2003
1Protein AggregatesIBA
07/2003
1UbiquitinIBA
07/2003
1Carrier Proteins (Binding Protein)IBA
07/2003

Therapy/Procedure

3Drug Therapy (Chemotherapy)
12/2021 - 02/2012
3Therapeutics
12/2021 - 02/2012
1Immunotherapy
10/2021
1Neoadjuvant Therapy
12/2020
1Precision Medicine
01/2015